靶向CK2α基因的siRNA对结肠癌HCT116细胞生长抑制作用及其机制

被引:4
作者
张霞
张秀梅
肖建英
机构
[1] 辽宁医学院基础学院生物化学教研室
关键词
酪蛋白激酶2; 结肠肿瘤; HCT116细胞; RNA干扰; 细胞周期;
D O I
10.13481/j.1671-587x.20140332
中图分类号
R735.35 [];
学科分类号
摘要
目的:探讨RNA干扰酪蛋白激酶2(CK2α)基因表达后对HCT116细胞生长的抑制作用并阐明其作用机制。方法:针对CK2α的mRNA序列设计CK2α-siRNA序列,将体外培养的HCT116细胞分为正常对照组(未转染)、阴性对照组(转染siRNA)和CK2α-siRNA组(转染CK2α-siRNA),应用Lipofectamine 2000进行转染,利用Western blotting法检测CK2α、cyclin H、P53和P21蛋白表达水平;应用MTT法检测各组HCT116细胞增殖;采用流式细胞术检测细胞周期时相的分布。结果:与阴性对照组比较,CK2α-siRNA组CK2α和细胞周期蛋白cyclin H的表达水平明显降低(P<0.01),P53蛋白表达水平无明显变化(P>0.05),P21蛋白表达水平则明显升高(P<0.01);MTT检测,与阴性对照组比较,转染48和72h,CK2α-siRNA组细胞存活率明显降低(P<0.01);流式细胞术分析,与阴性对照组比较,CK2α-siRNA组S期细胞所占比例逐渐减少(P<0.01),G1期细胞则明显增加(P<0.01),细胞滞留在G1期。结论:RNA干扰CK2α表达能够抑制HCT116细胞增殖,发生G1期阻滞;其机制可能与RNA干扰CK2α表达后cyclin H表达下调及P53活性恢复有关。
引用
收藏
页码:621 / 625
页数:5
相关论文
共 6 条
[1]
蛋白激酶CK2α特异性小干扰RNA对喉癌细胞生长的抑制作用 [J].
王建亭 ;
龚树生 ;
刘英鹏 ;
陈广理 .
中华耳鼻咽喉头颈外科杂志, 2006, (08) :617-621
[2]
Attenuation of β-Amyloid-Induced Tauopathy Via Activation of CK2α/SIRT1: Targeting for Cilostazol [J].
Lee, Hye Rin ;
Shin, Hwa Kyoung ;
Park, So Youn ;
Kim, Hye Young ;
Lee, Won Suk ;
Rhim, Byung Yong ;
Hong, Ki Whan ;
Kim, Chi Dae .
JOURNAL OF NEUROSCIENCE RESEARCH, 2014, 92 (02) :206-217
[3]
Molecular interplay between cdk4 and p21 dictates G0/G1 cell cycle arrest in prostate cancer cells [J].
Gulappa, Thippeswamy ;
Reddy, Ramadevi Subramani ;
Suman, Suman ;
Nyakeriga, Alice M. ;
Damodaran, Chendil .
CANCER LETTERS, 2013, 337 (02) :177-183
[4]
miR-150 promotes the proliferation of lung cancer cells by targeting P53 [J].
Zhang, Ni ;
Wei, Xiang ;
Xu, Lijun .
FEBS LETTERS, 2013, 587 (15) :2346-2351
[5]
Protein kinase CK2α subunit over-expression correlates with metastatic risk in breast carcinomas: Quantitative immunohistochemistry in tissue microarrays [J].
Giusiano, Sophie ;
Cachet, Claude ;
Filhol, Odile ;
Duchemin-Pelletier, Eve ;
Secq, Veronique ;
Bonnier, Pascal ;
Carcopino, Xavier ;
Boubli, Leon ;
Birnbaum, Daniel ;
Garcia, Stephane ;
Iovanna, Juan ;
Charpin, Colette .
EUROPEAN JOURNAL OF CANCER, 2011, 47 (05) :792-801
[6]
CIGB-300, a novel proapoptotic peptide that impairs the CK2 phosphorylation and exhibits anticancer properties both in vitro and in vivo [J].
Silvio E. Perea ;
Osvaldo Reyes ;
Idania Baladron ;
Yasser Perera ;
Hernán Farina ;
Jeovanis Gil ;
Arielis Rodriguez ;
Dania Bacardi ;
Jose L. Marcelo ;
Karelia Cosme ;
Marisol Cruz ;
Carmen Valenzuela ;
Pedro A. López-Saura ;
Yaquelin Puchades ;
Joem M. Serrano ;
Osmani Mendoza ;
Lila Castellanos ;
Aniel Sanchez ;
Lazaro Betancourt ;
Vladimir Besada ;
Ricardo Silva ;
Ernesto López ;
Viviana Falcón ;
Ignacio Hernández ;
Margarita Solares ;
Agueda Santana ;
Alina Díaz ;
Thelvia Ramos ;
Carlos López ;
Juan Ariosa ;
Luis J. González ;
Hilda Garay ;
Daniel Gómez ;
Roberto Gómez ;
Daniel F. Alonso ;
Hugo Sigman ;
Luis Herrera ;
Boris Acevedo .
Molecular and Cellular Biochemistry, 2008, 316 :163-167